MAROKO133 Update crypto: The Hantavirus Scare Brought 3 Covid-Era Stocks Back in the Spotl

📌 MAROKO133 Update crypto: The Hantavirus Scare Brought 3 Covid-Era Stocks Back in

The hantavirus outbreak on the MV Hondius lifted one mRNA leader 36% off May lows before profit-taking trimmed the rally. The brief move reactivated the pandemic-prep trade across medical stocks, putting three Covid-era stocks back on the 2026 comeback watchlist.

Each setup carries a different signal. One name has already moved on to the mRNA platform strength. Another builds an inverse base as the biodefense contractor. The third offers a contrarian play loaded with bears. May 2026 is when each chart picks a side.

Note: mRNA, short for messenger RNA, is the vaccine platform behind the COVID-19 shots, delivering genetic instructions to cells instead of using a live virus.

Moderna (NASDAQ: MRNA)

Among the Covid-era stocks rotating back into focus, Moderna stock rallied 36.08% from $43.69 on May 1 to $59.45 on May 11. Volume rose alongside price throughout the climb, confirming buying pressure rather than short covering.

Want more insights like this? Sign up for Editor Harsh Notariya’s Daily Newsletter here.

Three catalysts drove the move. Q1 2026 revenue grew 260% year-over-year to $389 million; the company disclosed a hantavirus vaccine collaboration with the US Army Medical Research Institute of Infectious Diseases; and Phase 3 mRNA-1010 flu data were published in the New England Journal of Medicine.

Moderna’s price now sits near $54.05, consolidating in what resembles the handle of a cup-and-handle continuation pattern. The cup bottom anchors at $43.69, and the rim sits near $59.45.

The handle is forming above the 20-day Exponential Moving Average (EMA), a trend indicator that weights recent price action more heavily, currently at $50.50.

Cup-and-handle patterns can fail if the handle retraces deeper than half the cup, which would put the bullish thesis in question.

The pattern stays valid as long as $51.17 holds. A daily close below opens the way to the 20-day EMA at $50.50 and the 50-day EMA at $49.75. A break under $43.69 invalidates the pattern entirely.

A daily close above $54.91 starts the handle breakout. A move above $60.96, which aligns with the upward-sloping neckline and the 0.618 Fibonacci level, confirms the breakout and projects a measured move to $81.46, roughly 33.59% above current levels.

Moderna already took its leg up. A smaller name (EBS) behind the US pandemic stockpile has not.

Emergent BioSolutions (NYSE: EBS)

Among the Covid-era stocks with the steepest drawdowns, Emergent stock manufactured Johnson & Johnson’s COVID-19 vaccine at its Baltimore Bayview facility under a $480 million contract. A 2021 contamination scandal that ruined 15 million doses then triggered a multi-year de-rating.

The stock corrected 44.36% from $14.07 to $7.53 earlier this year. The trigger was Emergent guiding FY26 revenue to $720-760 million on March 1, below consensus.

A second leg followed on April 30, when Q1 2026 revenue fell 30% year-over-year to $156.1 million, driven by weaker sales of anthrax and smallpox medical countermeasures.

That second dip created the head of an inverse head-and-shoulders pattern. The left shoulder formed near $7.82 in late March. The head dipped to $7.53 in early May. The right shoulder is now forming at $8.33 with visibly weaker selling pressure. That weakening pressure suggests the de-rating may have exhausted.

Inverse head-and-shoulders patterns fail when the right shoulder dips below the head, which would put the floor in question.

A daily close below $8.33 weakens the structure. A break under $7.53 invalidates the pattern entirely.

A daily close above $10.02, which aligns with the neckline and the 0.786 Fibonacci level, confirms the breakout. The measured move projects 25.76% upside toward $12.65, with the prior high at $14.07 capping the extended target.

Emergent’s pattern is set. The final chart shows the contrarian mRNA name loaded with bear positioning.

BioNTech (NASDAQ: BNTX)

Among the Covid-era stocks with the most direct mRNA platform pedigree, <a href="https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2021-financia…

Konten dipersingkat otomatis.

🔗 Sumber: www.beincrypto.com

📌 MAROKO133 Eksklusif crypto: SharpLink’s Ethereum Bet Just Generated a $686 Milli

SharpLink posted a Q1 2026 net loss of nearly $686 million, driven almost entirely by $507 million in unrealized losses from its Ethereum treasury, a figure that dwarfs the firm’s less than $1 million loss in the same period last year. Bearish news for ETH treasuries.

The trigger was a 45% peak-to-trough ETH drawdown that turned the company’s aggressive accumulation strategy into a paper catastrophe under GAAP fair-value accounting rules.

The same earnings release announced a $125 million on-chain yield fund with Galaxy Digital, which some analysts are reading as a lifeline in disguise.

The tension at the center of this story is real: does the Galaxy deal signal institutional confidence in ETH staking infrastructure, or does it signal that SharpLink needed a structural backstop to stay credible? Those are not the same thing.

How a 45% ETH Drawdown Produced a $686M Loss, and Why the Math Works That Way

The mechanism here is worth understanding precisely, because it is not a trading loss or an operational failure in the traditional sense.

SharpLink holds approximately 872,984 ETH valued at roughly $2.1 billion at current prices. GAAP fair-value accounting requires the firm to mark those holdings to market at each reporting date, which means a price decline flows directly into the income statement as an unrealized loss – no ETH sold, no cash out the door.

ETH fell from approximately $3,354 on January 15, 2026, to $2,104 by March 31 – a drop of roughly 37% over the quarter alone, contributing the bulk of that $507 million unrealized hit.

Across the broader peak-to-trough cycle, the 45% ETH drawdown compressed the dollar value of SharpLink’s entire treasury position with mechanical precision. The larger the ETH stack, the larger the paper loss on the way down.

The staking revenue side did not come close to offsetting this. Q1 2026 revenues jumped to more than $12 million from under $1 million a year earlier, a genuine operational improvement powered by the firm’s staked Ethereum treasury.

SharpLink has accumulated 18,800 ETH in staking rewards since launching its treasury strategy in June 2025, running a mix of 66% native staking, 33% liquid staking, and 1% restaking. That is a functioning yield engine. It is just not a $507 million yield engine.

The distinction that matters analytically: this is not a validator economics failure, nor a leverage blowup. It is a concentration risk event, amplified by accounting standards that require mark-to-market recognition of assets that have not been liquidated.

SharpLink ended Q1 with $16.9 million in cash and 872,984 ETH still on its books. The loss is real on paper. The ETH is still there.

That said, the accounting and liquidity risks in institutional Ethereum staking operations are not theoretical. A 45% drawdown does not just create paper losses; it compresses the equity cushion that supports the entire treasury model and raises legitimate questions about what a further leg down would look like on the balance sheet.

Ethereum News: The Galaxy Digital Fund Is a Signal, But Not Necessarily the One Being Advertised

The $125 million on-chain yield fund announced alongside the Q1 results is structured as follows: $100 million comes from SharpLink’s staked ETH treasury, and $25 million from Galaxy Digital. Galaxy is responsible for protocol selection, exposure sizing, and ongoing monitoring of all on-chain deployments.

SharpLink brings the capital. Galaxy brings the operational oversight.

Galaxy Digital CEO Mike Novogratz framed the deal in sector terms: “Institutional capital is moving on-chain, and the infrastructure to support it has matured to a point where allocators can access yield, liquidity, and risk management with the same rigor they expect in traditional markets.”

That is a bullish read on institutional crypto broadly, and Galaxy’s own stock performance supports the narrative. GLXY shares are up 43% in the last month, recently trading at $30.92.

SharpLink CEO Joseph Chalom described the strategic direction as moving “beyond foundational staking into a broader set of on-chain opportunities,” emphasizing a “comprehensive risk-management framework” designed to deliver shareholder value across market cycles.

The language is disciplined. The timing raises a question worth naming: a firm reporting a $686 million quarterly loss is not negotiating from a position of strength.

The conflict of interest embedded in this structure is also worth naming. Galaxy is both a financial contributor to the fund and the entity managing its on-chain deployment decisions.

That does not make the partnership wrong. It does mean the assumption that Galaxy’s protocol selection is purely independent of its own positioning deserves scrutiny from investors and analysts watching this sector.

If ETH price recovers meaningfully through Q2 and Q3, the fund launch will look like a well-timed DeFi pivot that turned a paper-loss narrative into a yield-diversification story.

If ETH continues to grind lower, the $100 million deployed from SharpLink’s treasury into on-chain protocols will be exposed to additional mark-to-market pressure on top of the core holdings. The asymmetry runs in both directions.

The post <a href="https://cryptonews.com/news/sharplink-686m…

Konten dipersingkat otomatis.

🔗 Sumber: cryptonews.com